Avacta Group (LON:AVCT) Stock Price Down 1.6% – Should You Sell?

Avacta Group Plc (LON:AVCT – Get Free Report) shares were down 1.6% on Monday. The company traded as low as GBX 56 and last traded at GBX 57.10. 797,066 shares traded hands during mid-day trading, a decline of 56% from the average daily volume of 1,797,769 shares. The stock had previously closed at GBX 58.02.

Avacta Group Stock Down 1.6%

The company has a debt-to-equity ratio of 526.98, a current ratio of 0.95 and a quick ratio of 4.96. The company has a market cap of Ā£249.89 million, a price-to-earnings ratio of -6.18 and a beta of 1.12. The firm’s 50 day simple moving average is GBX 66.49 and its 200-day simple moving average is GBX 68.70.

Avacta Group (LON:AVCT – Get Free Report) last issued its quarterly earnings data on Wednesday, September 30th. The biotechnology company reported GBX (4.23) earnings per share (EPS) for the quarter. Avacta Group had a negative return on equity of 1,293.07% and a negative net margin of 35,730.97%. As a group, sell-side analysts anticipate that Avacta Group Plc will post -9.90 earnings per share for the current year.

Avacta Group Company Profile

(Get Free Report)

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISIONĀ® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

Further Reading

Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.